Evidence map›Paper›PMID 40646688›Full record

ReviewTranscription

Orphan nuclear receptor transcription factors as drug targets.

Stephen Safe, Arafat R Oany, Wai Ning Tsui, Miok Lee, Vinod Srivastava, Srijana Upadhyay, Amanuel Hailemariam, Evan Farkas, Sarah Kakwan, Caitrina Kearns and 1 more

RetractedAbstract readReviewRetracted Publication
In one paragraph

Review in Transcription. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Structural modeling supports an interaction between thebioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. NADAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  4. Review
  5. Neuregulin 4 in Insulin Resistance: Mechanisms, Controversies, and Therapeutic Perspectives.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Stephen SafeDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.ORCID 0000-0002-2115-3060
Arafat R OanyDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.
Wai Ning TsuiDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.
Miok LeeDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
Vinod SrivastavaDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.
Srijana UpadhyayDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.
Amanuel HailemariamDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.
Evan FarkasDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.
Sarah KakwanDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
Caitrina KearnsDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
Gargi SivaramDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.

Funding

Texas A&M Center for Environmental Health Research (TiCER)P30ES029067 · NIEHS · TEXAS A&M UNIVERSITY · PI Sakhila Banu · 2019 to 2026
$13.0M
Regulatory Science in Environmental Health and ToxicologyT32ES026568 · NIEHS · TEXAS A&M UNIVERSITY · PI Weihsueh A Chiu, Natalie M Johnson · 2016 to 2026
$3.8M
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune SurveillanceR01CA269580 · NCI · TEXAS A&M UNIVERSITY · PI MAEN ABDELRAHIM, James Jing Cai · 2023 to 2026
$2.3M
NCI NIH HHS R01 CA269580NIEHS NIH HHS P30 ES029067NIEHS NIH HHS T32 ES026568
6 · The paper itself

Abstract

The nuclear receptor (NR) superfamily of ligand-activated receptors plays a key role in maintaining cellular homeostasis and in pathophysiology. NRs can be subdivided into functional activities structural similarity and the existence of endogenous ligands. Most NRs are classified as those that are adopted orphan or orphan receptors which have only possible ligands or no identified endogenous ligands, respectively. In this review, the activities of the complete orphan receptor sub-family of transcription factors have been reviewed with a focus on the effects of possible endogenous (biochemicals), natural product-derived and synthetic ligands. Despite their lack of a bona-fide ligand, the orphan receptors bind structurally diverse compounds that exhibit tissue-specific agonist, antagonist and inverse agonist activities with potential for future development as clinical therapeutics for the treatment of multiple diseases.

Indexed as

Orphan Nuclear ReceptorsTranscription FactorsAnimalsHumansLigandsLigandsOrphan Nuclear ReceptorsTranscription FactorsligandsOrphan nuclear receptorstranscription

Identifiers

PMID40646688
PMCPMC12263127

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.